Free Trial

Protagonist Therapeutics (PTGX) 10K Form and Latest SEC Filings 2026

Protagonist Therapeutics logo
$99.21 -0.31 (-0.31%)
Closing price 04:00 PM Eastern
Extended Trading
$105.75 +6.54 (+6.59%)
As of 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Protagonist Therapeutics SEC Filings & Recent Activity

Protagonist Therapeutics (NASDAQ:PTGX) has submitted 410+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Protagonist Therapeutics's financial statements. The most recent filing was a Form SCHEDULE 13G submitted on April 30, 2026.

Form 4
Protagonist Therapeutics, Inc Reports Ownership Change on Apr. 21, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

10-Q
Protagonist Therapeutics Files Quarterly Report on Nov. 6, 2025

The 10-Q contains Protagonist Therapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Protagonist Therapeutics SEC Filing History

Browse Protagonist Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/30/2026 10:57 AM
Protagonist Therapeutics (1377121) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/29/2026 1:43 PM
Protagonist Therapeutics (1377121) Subject
VANGUARD PORTFOLIO MANAGEMENT LLC (2100121) Filed by
Form SCHEDULE 13G
04/28/2026 3:54 PM
Protagonist Therapeutics (1377121) Filer
Form ARS
04/28/2026 3:44 PM
Protagonist Therapeutics (1377121) Filer
Form DEF 14A
04/28/2026 3:50 PM
Protagonist Therapeutics (1377121) Filer
Form DEFA14A
04/21/2026 3:57 PM
Ali Asif (1921163) Reporting
Protagonist Therapeutics (1377121) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/21/2026 3:58 PM
Ali Asif (1921163) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2026 6:34 PM
Protagonist Therapeutics (1377121) Issuer
SELICK HAROLD E (1287233) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2026 6:36 PM
MOLINA ARTURO MD (1398940) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2026 6:33 PM
Ali Asif (1921163) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2026 10:33 AM
Protagonist Therapeutics (1377121) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/25/2026 6:23 PM
PATEL DINESH V PH D (1120477) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/24/2026 4:56 PM
PATEL DINESH V PH D (1120477) Reporting
Protagonist Therapeutics (1377121) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/18/2026 5:12 PM
Protagonist Therapeutics (1377121) Issuer
Williams Lewis T (1475714) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 4:27 PM
Protagonist Therapeutics (1377121) Subject
Williams Lewis T (1475714) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/17/2026 7:41 AM
Protagonist Therapeutics (1377121) Subject
RTW INVESTMENTS, LP (1493215) Filed by
Form SCHEDULE 13G/A
02/10/2026 10:19 AM
Protagonist Therapeutics (1377121) Subject
Form SCHEDULE 13G
02/06/2026 3:38 PM
Protagonist Therapeutics (1377121) Issuer
Waddill William D. (1553338) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/06/2026 3:10 PM
Farallon Capital Partners, L.P. (1175707) Filed by
Protagonist Therapeutics (1377121) Subject
Form SCHEDULE 13G/A
01/30/2026 1:43 PM
Protagonist Therapeutics (1377121) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
01/27/2026 8:19 PM
MOLINA ARTURO MD (1398940) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 8:20 PM
Ali Asif (1921163) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 8:21 PM
PATEL DINESH V PH D (1120477) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/27/2026 4:12 PM
Ali Asif (1921163) Reporting
Protagonist Therapeutics (1377121) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/26/2026 3:29 PM
MOLINA ARTURO MD (1398940) Reporting
Protagonist Therapeutics (1377121) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/23/2026 3:06 PM
PATEL DINESH V PH D (1120477) Reporting
Protagonist Therapeutics (1377121) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/21/2026 4:15 PM
Ali Asif (1921163) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 4:16 PM
PATEL DINESH V PH D (1120477) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 4:17 PM
MOLINA ARTURO MD (1398940) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 4:10 PM
Ali Asif (1921163) Reporting
Protagonist Therapeutics (1377121) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/21/2026 4:11 PM
PATEL DINESH V PH D (1120477) Reporting
Protagonist Therapeutics (1377121) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/21/2026 4:12 PM
MOLINA ARTURO MD (1398940) Reporting
Protagonist Therapeutics (1377121) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/13/2026 3:45 PM
Protagonist Therapeutics (1377121) Issuer
SELICK HAROLD E (1287233) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 7:00 AM
Protagonist Therapeutics (1377121) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/06/2026 6:37 PM
Ali Asif (1921163) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 6:38 PM
PATEL DINESH V PH D (1120477) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 6:39 PM
O'Dowd Sarah A (1447149) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 6:40 PM
Protagonist Therapeutics (1377121) Issuer
Williams Lewis T (1475714) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 6:41 PM
Giraudo Bryan (1740847) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 6:42 PM
Protagonist Therapeutics (1377121) Issuer
Waddill William D. (1553338) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 6:44 PM
Protagonist Therapeutics (1377121) Issuer
SELICK HAROLD E (1287233) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 6:35 PM
MOLINA ARTURO MD (1398940) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:01 PM
MOLINA ARTURO MD (1398940) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 7:23 AM
Deep Track Capital, LP (1856083) Filed by
Protagonist Therapeutics (1377121) Subject
Form SCHEDULE 13G/A
11/06/2025 3:52 PM
Protagonist Therapeutics (1377121) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2025 3:19 PM
Protagonist Therapeutics (1377121) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/17/2025 5:24 PM
BlackRock, Inc. (2012383) Filed by
Protagonist Therapeutics (1377121) Subject
Form SCHEDULE 13G/A
10/14/2025 3:01 PM
Protagonist Therapeutics (1377121) Issuer
Waddill William D. (1553338) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/10/2025 3:18 PM
Protagonist Therapeutics (1377121) Subject
Waddill William D. (1553338) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/24/2025 7:35 PM
Protagonist Therapeutics (1377121) Issuer
Waddill William D. (1553338) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2025 4:35 PM
PATEL DINESH V PH D (1120477) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
08/29/2025 4:30 PM
Protagonist Therapeutics (1377121) Issuer
Waddill William D. (1553338) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/27/2025 3:33 PM
Protagonist Therapeutics (1377121) Subject
Waddill William D. (1553338) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/11/2025 7:04 AM
Protagonist Therapeutics (1377121) Subject
STATE STREET CORP (93751) Filed by
STATE STREET CORP (93751) Filed by
Form SCHEDULE 13G
07/28/2025 5:08 PM
PATEL DINESH V PH D (1120477) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/23/2025 5:57 PM
PATEL DINESH V PH D (1120477) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025 3:08 PM
Protagonist Therapeutics (1377121) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/16/2025 4:30 PM
BIOTECHNOLOGY VALUE FUND L P (918923) Filed by
Protagonist Therapeutics (1377121) Subject
Form SCHEDULE 13G
06/11/2025 4:40 PM
MOLINA ARTURO MD (1398940) Reporting
Protagonist Therapeutics (1377121) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2025 4:51 PM
MOLINA ARTURO MD (1398940) Reporting
Protagonist Therapeutics (1377121) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/09/2025 3:46 PM
MOLINA ARTURO MD (1398940) Reporting
Protagonist Therapeutics (1377121) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/13/2025 11:10 AM
Protagonist Therapeutics (1377121) Subject
STATE STREET CORP (93751) Filed by
STATE STREET CORP (93751) Filed by
Form SCHEDULE 13G
05/06/2025 3:27 PM
Protagonist Therapeutics (1377121) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Protagonist Therapeutics SEC Filings - Frequently Asked Questions

Protagonist Therapeutics (PTGX) has submitted 410+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Protagonist Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Protagonist Therapeutics's financial statements page.

The most recent filing was a Form SCHEDULE 13G submitted on April 30, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:PTGX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners